What is the recommended dose and administration schedule for Prevnar 20 (20-valent pneumococcal conjugate vaccine) in infants, children, and adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Prevnar 20 Dosing Recommendations

Prevnar 20 is administered as a 4-dose series at 2,4,6, and 12-15 months of age for infants, with the first dose given as early as 6 weeks; children and adolescents receive catch-up dosing based on age and prior vaccination history, while adults ≥18 years receive a single 0.5 mL intramuscular dose. 1

Infants and Young Children (6 Weeks Through 15 Months)

Standard 4-Dose Series

  • Doses administered at: 2,4,6, and 12-15 months of age
  • Minimum age for first dose: 6 weeks
  • Minimum interval: 4 weeks between infant doses (doses 1-3); at least 8 weeks between dose 3 and dose 4
  • Fourth dose timing: Must be given at least 2 months after the third dose 1

Important consideration for premature infants: For infants born at <37 weeks gestation who are medically stable, administer PCV20 at the recommended chronologic age (not corrected age) concurrent with other routine vaccinations. Monitor for apnea following vaccination in premature infants, as this has been observed with intramuscular vaccines in this population 1

Catch-Up Vaccination (7 Months Through 17 Years)

Previously Unvaccinated Children

Ages 7-11 months:

  • 3 doses total
  • First 2 doses: at least 4 weeks apart
  • Third dose: at 12-15 months, at least 8 weeks after the second dose 1

Ages 12-23 months:

  • 2 doses total
  • Interval: at least 8 weeks apart 1

Ages 24 months through 17 years:

  • 1 dose only 1

Previously Vaccinated with Lower Valency PCV (PCV7, PCV13, or PCV15)

For children 15 months through 17 years:

  • Administer a single dose of Prevnar 20
  • Minimum interval: At least 8 weeks after the last dose of the lower valency pneumococcal conjugate vaccine 1

This applies regardless of how many prior doses of PCV7, PCV13, or PCV15 were received, ensuring coverage of the 7 additional serotypes in PCV20 (serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F).

Adults (≥18 Years of Age)

Single 0.5 mL intramuscular dose 1

As of October 2024, ACIP expanded recommendations to include all adults ≥50 years of age who have not previously received a pneumococcal conjugate vaccine 2. Previously, the age-based recommendation began at 65 years.

Special Populations in Adults

  • Immunocompromised individuals: Consider vaccination on an individual basis, as safety and immunogenicity data are limited in this population. Altered immunocompetence may result in reduced immune responses 1
  • High-risk conditions: Adults 19-49 years with certain risk conditions should receive PCV per existing ACIP recommendations 2

Administration Details

Preparation and Injection Technique

  1. Shake vigorously until homogeneous white suspension is achieved
  2. Visual inspection: Do not use if large particulate matter or discoloration present
  3. Remove syringe cap by turning counterclockwise
  4. Attach sterile needle appropriate for intramuscular administration
  5. Administer 0.5 mL intramuscularly 1

Critical caveat: Do not mix Prevnar 20 with other vaccines or products in the same syringe 1

Safety Profile

The most common adverse reactions vary by age group:

Infants (4-dose series): Irritability (>60%), injection site pain (>30%), drowsiness (>30%), decreased appetite and injection site redness (>20%), injection site swelling and fever (>10%) 1, 3

Children 15 months-17 years: Pain at injection site (>50%), irritability in younger children (>60% if <2 years), drowsiness in younger children (>40% if <2 years), fatigue and muscle pain in older children (>20% if ≥2 years) 1, 4

Adults 18-59 years: Injection site pain (>70%), muscle pain (>50%), fatigue (>40%), headache (>30%), arthralgia and injection site swelling (>10%) 1

Adults ≥60 years: Injection site pain (>50%), muscle pain and fatigue (>30%), headache (>20%), arthralgia (>10%) 1

Most reactions are mild to moderate in severity. The safety profile of PCV20 is similar to PCV13 across all age groups 3, 5, 6, 4

Contraindications

Absolute contraindication: Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20 or to diphtheria toxoid 1

References

Related Questions

Does the 20-valent pneumococcal conjugate vaccine (Pneumococcal 20), Jardiance (empagliflozin), or metformin contain gluten?
Can the 20-valent pneumococcal conjugate vaccine (Prevnar 20) be administered concurrently with the seasonal influenza vaccine?
In an 8-year-old male with low pneumococcal antibody titers but normal titers for other vaccines and frequent upper respiratory infections, should he receive the 20‑valent pneumococcal conjugate vaccine (Prevnar 20) or the 23‑valent pneumococcal polysaccharide vaccine (PPSV23)?
What is the recommended interval and method for administering both Prevnar 20 (20‑valent pneumococcal conjugate vaccine) and CAPVAXIVE (13‑valent pneumococcal conjugate vaccine) in the same adult patient?
How many doses of PCV20 (20‑valent pneumococcal conjugate vaccine, Prevnar 20) are required for pediatric patients, including the routine schedule for healthy infants, recommendations for children with risk conditions, and catch‑up dosing?
Can the patient take telmisartan together with rosuvastatin?
How long does a Giemsa‑stained thin blood film take to produce a result?
What is the characteristic murmur of pulmonary stenosis?
Is transcutaneous electrical nerve stimulation (TENS) on the forehead safe for an adult with episodic migraine, what are the risks, and what intensity should be used?
Can atrial fibrillation cause an elevation of aspartate aminotransferase (AST) levels?
What are the predicted pre‑operative and post‑operative forced expiratory volume in one second (FEV1) values, their normal ranges, and the surgical indications based on these values?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.